Published on: October 10, 2024

The Health Technology Assessment (HTA) Philippines invites interested researchers to submit capsule proposals under the HTA Research Agenda Program: 2024 HTA Topics – Batch 3 Call [FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments]

  • This call consists of prioritized health technology topics that underwent clinical assessment under the HTA general track and are proceeding to the following assessments:
    • Economic assessment: Economic evaluation (EE), Budget Impact Analysis (BIA) and Household Financial Impact (HFI) Analysis
    • ELSHI assessment: Scoping review of ELSHI evidence (and systematic review and primary data collection, if deemed necessary)

The following are the health technology topics for economic and ELSHI assessments to be funded under this Call for Capsule Proposals:

HTA Topics for Economic Assessment

  • For Cost-Effectiveness/Utility Analysis (CEA/CUA)
    • Ranibizumab, Aflibercept and Dexamethasone as first-line treatment for Diabetic Macular Edema (DME)
    • Ranibizumab compared to Dexamethasone as first-line treatment for Macular Edema secondary to Retinal Vein Occlusion (ME-RVO)
    • Nilotinib compared with Imatinib for adult patients with Philadelphia-positive, chronic myeloid leukemia in chronic phase
  • For Cost-Minimization Analysis (CMA)
    • Ranibizumab compared to Aflibercept as first-line treatment for Wet Age-related Macular Degeneration (wAMD)

HTA topics for ELSHI Assessment

  • Ranibizumab, Aflibercept and Dexamethasone as first-line treatment for Diabetic Macular Edema (DME)
  • Ranibizumab compared to Dexamethasone as first-line treatment for Macular Edema secondary to Retinal Vein Occlusion (ME-RVO)
  • Ranibizumab compared to Aflibercept as first-line treatment for Wet Age-related Macular Degeneration (wAMD) 
  • Nilotinib compared with Imatinib for adult patients with Philadelphia-positive, chronic myeloid leukemia in chronic phase
  • Erdosteine compared to acetylcysteine or carbocisteine among adult patients with chronic obstructive pulmonary disease (COPD) GOLD GRADE 1 and above

For interested researchers, kindly take note of the following important dates:

  • Deadline of expression of interest: 24 October 2024 (Thursday)
  • Deadline of submission of requirements: 10 working days from the submission of expression of interest

Submissions shall be sent to htaresearch@dost.gov.ph

Kindly see the call guide and Terms of Reference for more info:

Call Guide:

Call-for-Proposals-Guidelines-Batch-3-Stream-1-EE_ELSHI-TopicsDownload

Terms of Reference:

ELSHI-Standard-TOR-Final-ELSHI-TOR_2024-Batch-3Download
CEA-for-DME-Final-EE-TOR_2024-Batch-3Download
CEA-for-MERVO-Final-EE-TOR_2024-Batch-3Download
CEA-for-Nilotinib-Final-EE-TOR_2024-Batch-3Download
CMA-for-wAMD-Final-EE-TOR_2024-Batch-3Download